Glaukos Corporation (GKOS) Stock Analysis
Breakout setup
Healthcare · Medical Devices
Sell if holding. Analyst target reached at $144.01 — A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (1.9% away).
Glaukos Corporation is a ophthalmic medical device and pharmaceutical company specializing in novel therapies for glaucoma, corneal health, and retinal disease. It earns revenue primarily from sales of the iStent and iDose trabecular micro-bypass devices and corneal health... Read more
Sell if holding. Analyst target reached at $144.01 — A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (1.9% away). Chart setup: Golden cross, above all MAs, RSI 70, MACD bullish. Score 5.4/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 74d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Glaukos Corporation
Latest news
- JP Morgan Maintains Overweight on Glaukos, Raises Price Target to $140 — benzinga Apr 30, 2026 positive
- Citigroup Maintains Buy on Glaukos, Raises Price Target to $140 — benzinga Apr 30, 2026 positive
- 12 Health Care Stocks Moving In Thursday's Intraday Session — benzinga Apr 30, 2026 neutral
- Caterpillar Posts Upbeat Q1 Results, Joins Garrett Motion, Wesco International, TTM Technologies And Other Big Stocks Mo — benzinga Apr 30, 2026 positive
- Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $138 — benzinga Apr 30, 2026 positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $144.01 — A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (1.9% away). Chart setup: Golden cross, above all MAs, RSI 70, MACD bullish. Prior stop was $133.93. Score 5.4/10, moderate confidence.
Take-profit target: $143.81 (-0.1% upside). Prior stop was $133.93. Stop-loss: $133.93.
Analyst target reached - limited upside remaining; Near 52-week high (1.9% away); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2).
Glaukos Corporation trades at a P/E of N/A (forward 300.5). TrendMatrix value score: 2.4/10. Verdict: Sell.
22 analysts cover GKOS with a consensus score of 4.2/5. Average price target: $151.
What does Glaukos Corporation do?Glaukos Corporation is a ophthalmic medical device and pharmaceutical company specializing in novel therapies for...
Glaukos Corporation is a ophthalmic medical device and pharmaceutical company specializing in novel therapies for glaucoma, corneal health, and retinal disease. It earns revenue primarily from sales of the iStent and iDose trabecular micro-bypass devices and corneal health products in the U.S. and internationally.